After a sleepy few months, the biotech IPO market is waking up thanks to back-to-back-to-back listings.
Oncology-focused Bicara Therapeutics, autoimmune startup Zenas BioPharma and metabolic …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus. We are doing our
Nektar Therapeutics said its former partner Eli Lilly had presented “erroneous data” for its atopic dermatitis drug before breaking off a $400 million alliance. Whereas
CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well as in person, according to a new study presented on Sunday